在癌症治疗领域，最近传来令人振奋的消息：安进公司（Amgen）研发的双特异性抗体疗法Blincyto（blinatumomab）已获得欧盟的批准，成为新确诊的费城染色体阴性CD19阳性B细胞前体急性淋巴细胞白血病（B-ALL）成人患者巩固治疗的一部分。这一里程碑式的批准，主要基于E1910临床3期试验的结果，显示出该疗法在提升患者生存率方面的巨大潜力。

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

Kansas children battling leukemia have a new hope for survival thanks to a new treatment available in Wichita. KU School of ...

In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute ...

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for pediatric leukemia is now available in Wichita.

In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.